Antidepressant Drugs Market Ready to Cross $15.9 Billion by 2023

Major Key Players:

The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Allied Market Research recently published a report, titled, “Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others): Global Opportunity Analysis and Industry Forecast, 2017-2023″. The report offers in-depth analyses of the global antidepressant drugs market by closely analyzing the industry trends, top investment pockets, drivers & opportunities, key growth strategies, and competitive landscape. According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.

Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market. However, poor efficacy and safety profiles of drugs, inclination toward non-pharmacological therapies, and increase in the number of patent expiration of antidepressants hamper the market growth. On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.

Download Sample Copy of this Report at: https://www.alliedmarketresearch.com/request-sample/2593

Obsessive-compulsive disorder segment to portray fastest demand through 2023

The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life. However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels. The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.

Selective serotonin reuptake inhibitors segment to lead the market by 2023

Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects. The other antidepressant products analyzed in the report are tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others.

Check available discounts on this report at: https://www.alliedmarketresearch.com/purchase-enquiry/2593

North America to retain the largest market share through 2023

North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region. However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population. The other regions analyzed in the report include Europe and Latin America, Middle East and Africa (LAMEA).

Source Medium: https://www.prnewswire.com/news-releases/antidepressant-drugs-market-to-reach-15-98-bn-by-2023-globally-at-2-1-cagr-says-allied-market-research-873540700.html

Scope Of The Report

Report Attribute	Details
Market size available for years	2017-2023
Base year considered	2018
Forecast period	2018-2023
Forecast units	Value (USD)
Segments covered	by Depressive Disorder, and Product
Geographies covered	North America, Europe, Asia-Pacific, LAMEA

Related Reports:

Anticoagulants Drugs Market by Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), Route of Administration (Oral Anticoagulant and Injectable Anticoagulant), and Application (Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Others) – Global Opportunity Analysis and Industry Forecast, 2018-2025

Cervical Cancer Drugs Market by Indication (Pre-malignant Lesions, Early Invasive Stage, and Advanced Invasive Stage), Treatment Type (Cryotherapy, Cold Knife Cone Biopsy, Simple Hysterectomy, Laser Surgery, Loop Electrosurgical Excision Procedure, Cone Biopsy, Radical Trachelectomy, Targeted Therapy, Chemotherapy, Radiation Therapy, and Hormone Therapy), and End User (Hospitals, Diagnostic Centers, Palliative Care Clinics, and Drug Store) – Global Opportunity Analysis and Industry Forecast, 2019-2026